Commercial laboratory seroprevalence survey data

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-ncov/index.html

Commercial laboratory seroprevalence survey data

Sept. 18, 2020
By National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. ...

[PDF-221.44 KB]

English

Details Supporting Files You May Also Like

Details:

Corporate Authors:

National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. ; United States. Department of Homeland Security. Cybersecurity and Infrastructure Security Agency‏.

National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. ; United States. Department of Homeland Security. Cybersecurity and Infrastructure Security Agency‏. Less -
Description:

Updated Sept. 18, 2020

CDC is partnering with commercial laboratories to conduct and publish results from a large-scale geographic seroprevalence survey that has tested de-identified clinical blood specimens from people in Connecticut, Louisiana, Minnesota, Missouri, the New York City metro area (Manhattan, Bronx, Queens, Kings, and Nassau), the Philadelphia metro area (Bucks, Chester, Cumberland, Delaware, Lancaster, Montgomery, Philadelphia), the San Francisco Bay Area (Marin, Contra Costa, Alameda, Santa Clara, San Mateo, and San Francisco), South Florida (Miami-Dade, Broward, Palm Beach, and Martin), Utah, and the Western Washington Region (King, Snohomish, Pierce, Kitsap, and Grays Harbor) for antibodies for the virus that causes COVID-19.

The survey includes people who had blood specimens tested for reasons unrelated to COVID-19, such as for a routine or sick visit during which blood was collected and tested by commercial laboratories in participating areas from each of the 10 sites. CDC aims to test about 1,800 samples collected from each of these 10 areas, approximately every 3–4 weeks. The results of these subsequent analyses are available on our interactive website and will be updated as samples continue to be analyzed. Researchers are looking to see what percentage of people tested already have antibodies against SARS-CoV-2, and how that percentage changes over time in each area.
Subjects:

[+]

Clinical Laboratory Services Coronavirus Infections/diagnosis COVID-19 Serological Testing Diagnostic Tests, Routine Seroepidemiologic Studies Serologic Tests
Document Type:

Webpage
Collection(s):

Stephen B. Thacker CDC Library
Main Document Checksum:

[+]

urn:sha256:91e89c8b8e7deca0dd2791badcb71dad147c4dcad687a01fadc839b1fc2bb8c1
Download URL:

https://stacks.cdc.gov/view/cdc/94058/cdc_94058_DS1.pdf
File Type:

commercial-lab-surveys.html

htm

More +